Screener
Collegium Pharmaceutical, Inc. COLL Segment — Stock-based compensation expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:34 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053851
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Corporate expenses | 12,163 | 9,801 | 26,703 | 23,090 |
| Medical expenses | 7,899 | 7,832 | 15,047 | 15,865 |
| Technical operations expenses | 165 | 136 | 415 | 234 |
| Stock-based compensation expense | 14,484 | 10,818 | 25,364 | 22,342 |
| Other segment items(1) | 25,480 | 577 | 31,655 | 2,477 |
| Interest expense | 19,519 | 20,463 | 35,381 | 41,253 |
| Interest income | (2,289) | (2,383) | (5,995) | (4,608) |
| Provision for income taxes | 1,519 | 5,042 | 5,763 | 5,747 |
Item 1. Condensed Consolidated Financial Statements (Unaudited).
FAQ
- What is Collegium Pharmaceutical, Inc.'s segment — stock-based compensation expense?
- Collegium Pharmaceutical, Inc. (COLL) reported segment — stock-based compensation expense of $14.48M in Q2 2026.
- How has Collegium Pharmaceutical, Inc.'s segment — stock-based compensation expense changed year-over-year?
- Collegium Pharmaceutical, Inc.'s segment — stock-based compensation expense increased by 33.9% year-over-year, from $10.82M to $14.48M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s segment — stock-based compensation expense?
- Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s segment — stock-based compensation expense has grown at a 22.4% compound annual growth rate (CAGR), from $22.87M to $41.91M.
- What does segment — stock-based compensation expense mean?
- Represents the non-cash expense recognized for equity-based awards granted to employees and executives as part of their compensation packages. This metric is used to evaluate the cost of talent retention and its impact on overall profitability.
Ask your AI about Collegium Pharmaceutical, Inc.'s segment — stock-based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude